Youcef M. Rustum

University of Iowa — United States

Medicine · Health Sciences

55h-index9.9kcitations306works0.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Colorectal Cancer Treatments and Studies(69), Cancer therapeutics and mechanisms(48), Cancer Treatment and Pharmacology(39), Cancer, Hypoxia, and Metabolism(33), Drug Transport and Resistance Mechanisms(28)

Publications306 total

Abstract C010: Anti-FN14 CAR-T cells overcome TGF-β-mediated suppression, and their synergy with methylseleninic acid enhances cytotoxicity and effector function in kidney, prostate, and brain tumors
Cancer Immunology Research·2026
Supplementary Table 3 from Phase I Clinical Trial of High Doses of Seleno-L-methionine in Combination with Axitinib in Patients with Previously Treated Metastatic Clear-cell Renal Cell Carcinoma
2025Open Access
Data from Phase I Clinical Trial of High Doses of Seleno-L-methionine in Combination with Axitinib in Patients with Previously Treated Metastatic Clear-cell Renal Cell Carcinoma
2025Open Access
Supplementary Data1 from Phase I Clinical Trial of High Doses of Seleno-L-methionine in Combination with Axitinib in Patients with Previously Treated Metastatic Clear-cell Renal Cell Carcinoma
2025Open Access
Phase I Clinical Trial of High Doses of Seleno-L-methionine in Combination with Axitinib in Patients with Previously Treated Metastatic Clear-cell Renal Cell Carcinoma
Clinical Cancer Research·2025Open Access
Targeting transforming growth factor-β1 by methylseleninic acid/seleno-L-methionine in clear cell renal cell carcinoma: Mechanisms and therapeutic potential
Cancer Treatment and Research Communications·2024· 2 citedOpen Access
Druggable Biomarkers Altered in Clear Cell Renal Cell Carcinoma: Strategy for the Development of Mechanism-Based Combination Therapy
International Journal of Molecular Sciences·2023· 9 citedOpen Access
MicroRNA Expression in Clear Cell Renal Cell Carcinoma Cell Lines and Tumor Biopsies: Potential Therapeutic Targets
International Journal of Molecular Sciences·2022· 8 citedOpen Access
Potential Role of Selenium in the Treatment of Cancer and Viral Infections
International Journal of Molecular Sciences·2022· 62 citedOpen Access
Phase I with expansion clinical trial of seleno-l-methionine (SLM) in combination with axitinib in patients with relapsed clear cell renal cell carcinoma (ccRCC): Bench to bedside.
Journal of Clinical Oncology·2021· 1 cited
PD39-02 RESULTS OF PHASE 1 CLINICAL TRIAL OF HIGH DOSES OF SELENO-L-METHIONINE (SLM) IN SEQUENTIAL COMBINATION WITH AXITINIB IN PREVIOUSLY TREATED AND RELAPSED CLEAR CELL RENAL CARCINOMA (CCRCC) PATIENTS
The Journal of Urology·2020· 1 citedOpen Access
Results of phase I clinical trial of high doses of seleno-l-methionine (SLM) in sequential combination with axitinib in previously treated and relapsed clear cell renal carcinoma (ccRCC) patients
Annals of Oncology·2019Open Access
Pleiotropic Action of Selenium in the Prevention and Treatment of Cancer, and Related Diseases
2019· 1 citedOpen Access
Preliminary results of phase I clinical trial of high doses of seleno-L-methionine (SLM) in sequential combination with axitinib in previously treated and relapsed clear cell renal cell carcinoma (ccRCC) patients.
Journal of Clinical Oncology·2019· 5 cited
Current Landscape and the Potential Role of Hypoxia-Inducible Factors and Selenium in Clear Cell Renal Cell Carcinoma Treatment
International Journal of Molecular Sciences·2018· 40 citedOpen Access
Non-Coding Micro RNAs and Hypoxia-Inducible Factors Are Selenium Targets for Development of a Mechanism-Based Combination Strategy in Clear-Cell Renal Cell Carcinoma—Bench-to-Bedside Therapy
PMC·2018
Non-Coding Micro RNAs and Hypoxia-Inducible Factors Are Selenium Targets for Development of a Mechanism-Based Combination Strategy in Clear-Cell Renal Cell Carcinoma—Bench-to-Bedside Therapy
International Journal of Molecular Sciences·2018· 26 citedOpen Access
Current Landscape and the Potential Role of HIF and Selenium in Clear Cell Renal Cell Carcinoma Treatment
Preprints.org·2018· 4 citedOpen Access
Phase1 clinical trial of high doses of Seleno-L-methionine (SLM), in sequential combination with axitinib in previously treated and relapsed clear cell renal cell carcinoma (ccRCC) patients.
Journal of Clinical Oncology·2018· 9 cited
Selenium targets resistance biomarkers enhancing efficacy while reducing toxicity of anti-cancer drugs: preclinical and clinical development
Oncotarget·2018· 39 citedOpen Access
page 1 of 16Next →

Frequent Co-authors

Shousong Cao(11), Harry K. Slocum(8), Károly Tóth(7), Patrick J. Creaven(6), Farukh A. Durrani(6), William R. Greco(5), U. Vanhoefer(4), A. Harstrick(4), Zlatko P. Pavelić(4), E. Mayhew(4), Nicholas J. Petrelli(3), S. Seeber(3), Constantine P. Karakousis(3), Oskar S. Frankfurt(3), Arnold I. Freeman(3), Mary M. Vaughan(3), L Herrera(2), A Mittelman(2), W. Achterrath(2), Hans‐Joachim Schmoll(2)